Abbott strikes $385m settlement over major formula recall
Abbott Laboratories agreed to pay $385m to settle US government claims related to its 2022 infant formula recall. The settlement resolves DOJ and state legal cases, with Abbott denying fault. The recall caused a US formula shortage. Abbott will pay $348.7m to the federal government and $36.3m to states. The DOJ accused Abbott of non-compliance and unsafe production practices. Abbott maintains its products were safe, citing negative tests for Cronobacter sakazakii.
How this was made
The 30-second read
Why it matters
The $385 M settlement ends DOJ and state claims, removing legal uncertainty but imposing a sizable cash cost.
Market read
First disclosure of a large settlement that could affect Abbott's stock price and sector sentiment.
What to watch
Abbott's strong cash flow and diversified portfolio may absorb the payment without major earnings impact.
Background
Abbott's Sturgis plant recall in 2022 led to a nationwide formula shortage and multiple lawsuits.
Ticker impact
Abbott Laboratories agreed to a $385 million settlement over its 2022 infant‑formula recall.
Potential short‑term downside of 3‑5% as investors reassess liability exposure.
A $385 M cash payment is material for a large cap health‑care company and the first public disclosure of the amount.
Market effects
May raise scrutiny on infant‑formula manufacturers and could affect peers in consumer health.
U.S. healthcare sector could see modest pressure as regulators focus on product safety.
Limited to U.S. markets; global peers may experience secondary sentiment spillover.
Counterpoint
The settlement resolves all litigation, potentially clearing a long‑standing cloud over the business.
Key entities
- CompanyAbbott Laboratories
U.S. healthcare company producing infant formula.
- Government AgencyU.S. Department of Justice
Filed the lawsuit leading to the settlement.
